Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of$ 0.13. This compares to a loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +7.69%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of$ 0.13 per share when it actually produced a loss of $0.13, delivering no surprise.Over the last four quarters, t ...